on August 18, 2003
Published online before print August 18, 2003, doi: 10.1161/01.CIR.0000087447.12918.85
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on March 13, 2003
From Duke Clinical Research Institute (C.B.G., K.W.M.), Durham, NC; Henry Ford Hospital (W.D.W.), Detroit, Mich; Montreal Heart Institute (P.T.), Montreal, Quebec, Canada; Columbia University (J.S.H.), New York, NY; Procter & Gamble Pharmaceuticals (T.G.F., T.G.T.), Mason, Ohio; Alexion Pharmaceuticals, Inc (S.R.), Cheshire, Conn; Heart Institute (J.C.N.), University of Sao Paulo Medical School, Sao Paulo, Brazil; National Institute of Cardiology (W.R.), Warsaw, Poland; and University of Alberta (P.W.A.), Edmonton, Alberta, Canada. * To whom correspondence should be addressed. E-mail: grang001{at}mc.duke.edu.
Background--Complement, activated during myocardial ischemia and reperfusion, causes myocardial damage through multiple processes. The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial was performed to determine the effect of pexelizumab, a C5 complement inhibitor, on infarct size in patients with ST-segment-elevation myocardial infarction (MI) undergoing primary percutaneous coronary intervention. Methods and Results--In COMMA, 960 patients with MI (20% isolated inferior MI) were randomized to placebo, pexelizumab 2.0-mg/kg bolus, or pexelizumab 2.0-mg/kg bolus and 0.05-mg/kg per h infusion for 20 hours. Infarct size by creatine kinase-MB area under the curve, the primary outcome, did not differ significantly between groups (placebo median, 4393; bolus pexelizumab, 4526; bolus plus infusion pexelizumab, 4713 [ng/mL] · h; P=0.89 for bolus versus placebo; P=0.76 for bolus plus infusion versus placebo), nor did the composite of 90-day death, new or worsening heart failure, shock, or stroke (placebo, 11.1%; bolus, 10.7%; bolus plus infusion, 8.5%). The ninety-day mortality rate was significantly lower with pexelizumab bolus plus infusion (1.8% versus 5.9% with placebo; nominal P=0.014); the bolus-only group had an intermediate mortality rate (4.2%). Conclusions--In patients with ST-elevation MI undergoing percutaneous coronary intervention, pexelizumab had no measurable effect on infarct size. However, the significant reduction in mortality suggests that pexelizumab may benefit patients through alternative novel mechanisms and provides impetus for additional investigation.
Revised on June 23, 2003
Accepted on June 24, 2003
Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction. The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) Trial
Christopher B. Granger MD*,
Key words: myocardial infarction • angioplasty • inflammation • reperfusion
This article has been cited by other articles:
 |
|
 |
|
  X. Luo, H. Cai, J. Ni, R. Bhindi, H. C. Lowe, C. N. Chesterman, and L. M. Khachigian c-Jun DNAzymes Inhibit Myocardial Inflammation, ROS Generation, Infarct Size, and Improve Cardiac Function After Ischemia-Reperfusion Injury Arterioscler Thromb Vasc Biol, November 1, 2009; 29(11): 1836 - 1842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Busche, V. Pavlov, K. Takahashi, and G. L. Stahl Myocardial ischemia and reperfusion injury is dependent on both IgM and mannose-binding lectin Am J Physiol Heart Circ Physiol, November 1, 2009; 297(5): H1853 - H1859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Frantz, J. Bauersachs, and G. Ertl Post-infarct remodelling: contribution of wound healing and inflammation Cardiovasc Res, February 15, 2009; 81(3): 474 - 481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Testa, W.J. Van Gaal, R. Bhindi, G.G.L. Biondi-Zoccai, A. Abbate, P. Agostoni, I. Porto, F. Andreotti, F. Crea, and A.P. Banning Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients. J. Thorac. Cardiovasc. Surg., October 1, 2008; 136(4): 884 - 893. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Abbate, C. Zoja, D. Corna, D. Rottoli, C. Zanchi, N. Azzollini, S. Tomasoni, S. Berlingeri, M. Noris, M. Morigi, et al. Complement-Mediated Dysfunction of Glomerular Filtration Barrier Accelerates Progressive Renal Injury J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1158 - 1167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Thibault, C. Piot, P. Staat, L. Bontemps, C. Sportouch, G. Rioufol, T. T. Cung, E. Bonnefoy, D. Angoulvant, J.-F. Aupetit, et al. Long-Term Benefit of Postconditioning Circulation, February 26, 2008; 117(8): 1037 - 1044. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Reynolds and J. S. Hochman Cardiogenic Shock: Current Concepts and Improving Outcomes Circulation, February 5, 2008; 117(5): 686 - 697. [Full Text] [PDF]
|
|
|
|
|
|
D. Seo and J. M. Hare The Transforming Growth Factor-{beta}/Smad3 Pathway: Coming of Age as a Key Participant in Cardiac Remodeling Circulation, November 6, 2007; 116(19): 2096 - 2098. [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Yellon and D. J. Hausenloy Myocardial Reperfusion Injury N. Engl. J. Med., September 13, 2007; 357(11): 1121 - 1135. [Full Text] [PDF]
|
|
|
|
|
|
M. T. Dirksen, G. J. Laarman, M. L. Simoons, and D. J.G.M. Duncker Reperfusion injury in humans: A review of clinical trials on reperfusion injury inhibitory strategies Cardiovasc Res, June 1, 2007; 74(3): 343 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The TRIUMPH Investigators Effect of Tilarginine Acetate in Patients With Acute Myocardial Infarction and Cardiogenic Shock: The TRIUMPH Randomized Controlled Trial JAMA, April 18, 2007; 297(15): 1657 - 1666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The APEX AMI Investigators Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial JAMA, January 3, 2007; 297(1): 43 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Eikelboom and M. O'Donnell Pexelizumab Does Not "Complement" Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction JAMA, January 3, 2007; 297(1): 91 - 92. [Full Text] [PDF]
|
|
|
|
 |
|
 T. K. Hansen, M.-A. Gall, L. Tarnow, S. Thiel, C. D. Stehouwer, C. G. Schalkwijk, H.-H. Parving, and A. Flyvbjerg Mannose-binding lectin and mortality in type 2 diabetes. Arch Intern Med, October 9, 2006; 166(18): 2007 - 2013. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Thielmann, G. Marggraf, M. Neuhauser, J. Forkel, U. Herold, M. Kamler, P. Massoudy, and H. Jakob Administration of C1-esterase inhibitor during emergency coronary artery bypass surgery in acute ST-elevation myocardial infarction. Eur. J. Cardiothorac. Surg., August 1, 2006; 30(2): 285 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. Mangano, Y. Miao, I. C. Tudor, C. Dietzel, for the Investigators of the Multicenter Study of, and and the Ischemia Research and Education Foundation Post-Reperfusion Myocardial Infarction: Long-Term Survival Improvement Using Adenosine Regulation With Acadesine J. Am. Coll. Cardiol., July 4, 2006; 48(1): 206 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Goyal, K. W. Mahaffey, J. Garg, J. C. Nicolau, J. S. Hochman, W. D. Weaver, P. Theroux, G. B.F. Oliveira, T. G. Todaro, C. F. Mojcik, et al. Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study Eur. Heart J., June 1, 2006; 27(11): 1289 - 1297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-C. Chang, P. Kaul, Y. Fu, C. M. Westerhout, C. B. Granger, K. W. Mahaffey, L. Wallentin, F. Van de Werf, P. W. Armstrong, and for the ASSENT-3 Investigators Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction Eur. Heart J., February 2, 2006; 27(4): 419 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. S. Speidl, M. Exner, J. Amighi, S. P. Kastl, G. Zorn, G. Maurer, O. Wagner, K. Huber, E. Minar, J. Wojta, et al. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis Eur. Heart J., November 1, 2005; 26(21): 2294 - 2299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Banz, O. M. Hess, S. C. Robson, D. Mettler, P. Meier, A. Haeberli, E. Csizmadia, E. Y. Korchagina, N. V. Bovin, and R. Rieben Locally targeted cytoprotection with dextran sulfate attenuates experimental porcine myocardial ischaemia/reperfusion injury Eur. Heart J., November 1, 2005; 26(21): 2334 - 2343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Collet and G. Montalescot The acute reperfusion management of STEMI in patients with impaired glucose tolerance and type 2 diabetes Diabetes and Vascular Disease Research, October 1, 2005; 2(3): 136 - 143. [Abstract] [PDF]
|
|
|
|
|
|
P. Theroux, P. W. Armstrong, K. W. Mahaffey, J. S. Hochman, K. J. Malloy, S. Rollins, J. C. Nicolau, J. Lavoie, T. M. Luong, J. Burchenal, et al. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial Eur. Heart J., October 1, 2005; 26(19): 1964 - 1970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Bonvini, T. Hendiri, and E. Camenzind Inflammatory response post-myocardial infarction and reperfusion: a new therapeutic target? Eur. Heart J. Suppl., October 1, 2005; 7(suppl_I): I27 - I36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. B. Danzi, L. Mauri, and F. Sozzi Percutaneous coronary intervention and beyond for ST-elevation acute myocardial infarction Eur. Heart J. Suppl., October 1, 2005; 7(suppl_K): K26 - K30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kohsaka, V. Menon, A. M. Lowe, M. Lange, V. Dzavik, L. A. Sleeper, J. S. Hochman, and for the SHOCK Investigators Systemic Inflammatory Response Syndrome After Acute Myocardial Infarction Complicated by Cardiogenic Shock Arch Intern Med, July 25, 2005; 165(14): 1643 - 1650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Libby and P. Theroux Pathophysiology of Coronary Artery Disease Circulation, June 28, 2005; 111(25): 3481 - 3488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S R Dixon Infarct angioplasty: beyond stents and glycoprotein IIb/IIIa inhibitors Heart, June 1, 2005; 91(suppl_3): iii2 - iii6. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Hovind, T. K. Hansen, L. Tarnow, S. Thiel, R. Steffensen, A. Flyvbjerg, and H.-H. Parving Mannose-Binding Lectin as a Predictor of Microalbuminuria in Type 1 Diabetes: An Inception Cohort Study Diabetes, May 1, 2005; 54(5): 1523 - 1527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Noris and G. Remuzzi Hemolytic Uremic Syndrome J. Am. Soc. Nephrol., April 1, 2005; 16(4): 1035 - 1050. [Full Text] [PDF]
|
|
|
|
|
|
R. A. Kloner and S. H. Rezkalla Cardiac protection during acute myocardial infarction: Where do we stand in 2004? J. Am. Coll. Cardiol., July 21, 2004; 44(2): 276 - 286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Hansen, L. Tarnow, S. Thiel, R. Steffensen, C. D. Stehouwer, C. G. Schalkwijk, H.-H. Parving, and A. Flyvbjerg Association Between Mannose-Binding Lectin and Vascular Complications in Type 1 Diabetes Diabetes, June 1, 2004; 53(6): 1570 - 1576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Antman and F. Van de Werf Pharmacoinvasive Therapy: The Future of Treatment for ST-Elevation Myocardial Infarction Circulation, June 1, 2004; 109(21): 2480 - 2486. [Full Text] [PDF]
|
|
|
|
|
|
E. D. Verrier, S. K. Shernan, K. M. Taylor, F. Van de Werf, M. F. Newman, J. C. Chen, M. Carrier, A. Haverich, K. J. Malloy, P. X. Adams, et al. Terminal Complement Blockade With Pexelizumab During Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass: A Randomized Trial JAMA, May 19, 2004; 291(19): 2319 - 2327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Beranek, C. B. Granger, K. W. Mahaffey, W. D. Weaver, P. Theroux, J. S. Hochman, T. G. Filloon, T. G. Todaro, S. Rollins, C. F. Mojcik, et al. Why Did the Anti-C5 Complement Antibody Pexelizumab Not Reduce Infarct Size but Influence Clinical Outcomes Positively When Applied as Adjunctive Therapy to Primary Percutaneous Coronary Intervention? * Response Circulation, April 27, 2004; 109(16): e195 - e196. [Full Text] [PDF]
|
|
|
|
|
|
W. W. O'Neill and S. R. Dixon The year in interventional cardiology J. Am. Coll. Cardiol., March 3, 2004; 43(5): 875 - 890. [Full Text] [PDF]
|
|
|
|
|
|
G. De Luca, A. W.J. van't Hof, M.-J. de Boer, J. C.A. Hoorntje, A.T. M. Gosselink, J.-H. E. Dambrink, J. P. Ottervanger, F. Zijlstra, and H. Suryapranata Impaired Myocardial Perfusion Is a Major Explanation of the Poor Outcome Observed in Patients Undergoing Primary Angioplasty for ST-Segment-Elevation Myocardial Infarction and Signs of Heart Failure Circulation, March 2, 2004; 109(8): 958 - 961. [Abstract] [Full Text] [PDF]
|
|